Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative

Neurobiol Aging. 2023 Jul:127:33-42. doi: 10.1016/j.neurobiolaging.2023.03.005. Epub 2023 Mar 10.


This study longitudinally examined participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) who underwent a conversion in amyloid-beta (Aβ) status in comparison to a group of ADNI participants who did not show a change in amyloid status over the same follow-up period. Participants included 136 ADNI dementia-free participants with 2 florbetapir positron emission tomography (PET) scans. Of these participants, 68 showed amyloid conversion as measured on florbetapir PET, and the other 68 did not. Amyloid converters and non-converters were chosen to have representative demographic data (age, education, sex, diagnostic status, and race). The amyloid converter group showed increased prevalence of APOE ε4 (p < 0.001), greater annualized percent volume loss in selected magnetic resonance imaging (MRI) regions (p < 0.05), lower cerebrospinal fluid Aβ1-42 (p < 0.001), and greater amyloid retention (as measured by standard uptake value ratios) on florbetapir PET scans (p < 0.001) in comparison to the non-converter group. These results provide compelling evidence that important neuropathological changes are occurring alongside amyloid conversion.

Keywords: Alzheimer’s disease; Amyloid; Cognition; Dementia; Magnetic resonance imaging; Positron emission tomography.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alzheimer Disease* / pathology
  • Amyloid
  • Amyloid beta-Peptides / metabolism
  • Aniline Compounds
  • Brain / metabolism
  • Cognitive Dysfunction* / pathology
  • Ethylene Glycols
  • Humans
  • Positron-Emission Tomography / methods


  • florbetapir
  • Aniline Compounds
  • Ethylene Glycols
  • Amyloid beta-Peptides
  • Amyloid